Posted by Michael Wonder on 16 Mar 2022
Dostarlimab for previously treated advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency
16 March 2022 - NICE has published evidence-based recommendations on the use of dostarlimab (Jemperli) for the treatment of adults with advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency.
Dostarlimab is recommended for use within the Cancer Drugs Fund as an option for the treatment of adults with advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency who have had platinum-based chemotherapy.
